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Summary
Objective/Background: Efficacy in osteoarthritis (OA) is principally measured using subjective visual analogue (VAS) and/or Likert scale
responses. The relationship between these two scales and their relative precision in discriminating active from placebo treatment in OA
patients was determined.
Design/Methods: Patient overall pain assessment, and patient and investigator global assessments were each measured on a 100 mm VAS
and on a 0 to 4 point Likert scale in a 6-week OA study of rofecoxib vs placebo. The relationship between the VAS and Likert responses was
examined graphically and via summary statistics. Analysis of variance was used to assess consistency of the VAS/Likert relationship over
time and across the different endpoints. Precision was compared using effect size, and normality of VAS scale of measurement was
assessed using the Shapiro–Wilk test.
Results: Mean VAS scores and changes from baseline at individual time points were generally highly correlated with corresponding Likert
responses (r-values generally approximately 0.7–0.8). The magnitude of VAS values and changes varied depending on endpoint, on the
associated magnitude of increment of Likert score, and on the Likert baseline value (i.e., where on the Likert scale the change was
occurring). Precision of VAS and Likert responses to detect difference between treatments was generally similar with effect sizes
approximately 1. Normality and homogeneity of variance of VAS scores was most closely approximated by actual changes in comparison to
percent change or log-transformed measures.
Conclusions: VAS and Likert responses are highly correlated and yield similar precision for discriminating treatments in OA patients. Since
Likert responses are easier to administer and interpret, they may be preferable to measure OA response.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Introduction
The evaluation of therapeutic efficacy in osteoarthritis (OA)
patients is principally based on subjective rating scale
responses to questions about pain, stiffness, function, and
overall evaluation. The visual analog (VAS) and Likert
scales are two major methods of measuring response to
subjective questions about OA efficacy. Both methods of
measurement were used in several efficacy questions in a
6-week, double blind, parallel group study of rofecoxib vs
placebo OA1. The purpose of this article is to describe the
relationship between the two types of scales and compare
their measurement characteristics.
In his text “Quality of Life Assessments in Clinical Trails”,
Spilker2 has written that both methods have their propo-
nents; however, there is a lack of evidence supporting a
rational choice between them. Guyatt et al.3 compared a
VAS with a 7-point Likert scale in the assessment of quality
of life in chronic pulmonary disease. They showed com-
parable levels of improvement in quality of life with both
methods, greater variability with the VAS, and recom-
mended the 7-point Likert scale over the VAS because of
its ease of use and interpretation. Streiner and Norman4
are also critical of the VAS. They reported that (1) subjects
had more difficulty with a VAS than with numerical or
adjectival scales; (2) a single item VAS is likely to demon-
strate low reliability; and (3) other methods may yield more
precise measurement, and possibly increased satisfaction
among respondents.
On the surface, it may appear that the VAS may have
better precision and be more sensitive to detect change
than Likert scales simply because of finer gradations of
levels of response. Preferred use of VAS has been en-
dorsed on this basis4. However, a large body of work does
not support this notion. Bellamy et al.5,6 found similar
relative efficiency (as a measure of precision) of the
100 mm VAS vs 5 point Likert scale responses using
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within-treatment changes from baseline of the WOMAC
Arthritis Index in patients with OA of the hip or knee. Jensen
et al.7 found similar magnitudes of correct response and
predictive validity of the following six rating scales in
chronic pain patients: 100 mm VAS, 0–100 point and 0–10
point numeric rating scales, and 4-, 5-, and 6-point Likert
scales. Downie et al.8 compared the measurement error of
a vertical and horizontal 100 mm VAS to that of a 4 point
Likert scale and a 0–10 point numeric rating scale. They
found the highest measurement error with the 4 point Likert
scale, and the lowest with the 0–10 point numeric rating
scale, with the VAS scales midway between them. Bellamy
et al.9,10 found a slight numeric advantage of the VAS over
the Likert scale in terms of effect size for pain measurement
in OA (one article) and in rheumatoid arthritis (second
article); however, both showed slight numeric advantage
over the McGill pain questionnaire.
Regarding the use of Likert scales, Streiner and
Norman4 claimed that respondents are unable to discrimi-
nate much beyond 7 levels. They reported that descriptions
of each level of response are preferred over descriptive
anchoring at only the ends because the latter tend to
increase variability by pulling responses towards the ends.
Response scales using only positive integers are preferable
to those using both negative and positive integers because
respondents tend to choose only positive numbered cat-
egories4. Unless the distribution of scores is severely
skewed, one can analyze data from Likert scales as if they
were interval without introducing severe bias.
Hence, there is the suggestion that use of Likert scales
may be as good as VAS, and almost certainly not substan-
tially worse. All of the previous work was based on single
respondent observations or on within-respondent changes
from baseline. The present report extends this work to a
placebo-controlled trial and centers the precision compari-
son on change from baseline difference between active
treatment and placebo. It further assesses the potential
usefulness of percent change and log transformation in the
analysis of VAS responses, and assesses the relationship
between the two scales by displaying specific magnitudes
of VAS changes for categories of Likert change from
baseline.
Materials and methods
Each of three OA efficacy questions were assessed
using both a 0–100 mm VAS and a 5 point Likert scale in a
6-week, double-blind, parallel group study of the effect of
rofecoxib vs placebo in 219 OA patients1 treated with
placebo (N72), rofecoxib 25 mg once daily (N73), or
rofecoxib 125 mg once daily (N74). The OA efficacy
questions and their respective VAS and Likert response
sets are described below; both response sets were used in
this Phase II trial (the first OA study of rofecoxib) to assess
their relative performance and support choices of endpoints
for Phase III trials. Each question was administered at the
prestudy visit (while patients were taking prior NSAID
therapy for OA), the baseline visit (after OA flare, i.e.,
meeting pre-specified criteria for worsening of OA symp-
toms during washout from prior NSAID therapy), treatment
Weeks 1, 2, 4, and 6 visits, and at the discontinuation visit
if the patient discontinued the study prematurely.
PATIENT PAIN ASSESSMENT (VAS)
“The following question concerns the amount of pain due
to arthritis in your study knee”.
VAS
“Please indicate the amount of pain recently experienced
by marking an (X) through the line:”
100 mm VAS scale—Left hand marker “no pain”, right
hand marker “extreme pain”.
Likert
“Please indicate the amount of pain recently experienced
by marking an (X) in one box below:”
M No pain
M Mild pain
M Moderate pain
M Severe pain
M Extreme pain
For analysis, the responses were assigned numeric
values 0 through 4, respectively.
PATIENT GLOBAL ASSESSMENT OF DISEASE STATUS
VAS
“Considering all the ways your arthritis affects you, mark
(X) on the scale for how well you are doing.” 100 mm VAS
scale—Left hand marker “Very well”, right hand marker
“Very poor”.
Likert
“Considering all the ways your arthritis affects you,
mark an (X) in one box below for how well you are doing.”
Very well, Well, Fair, Poor, Very poor. For analysis, the
responses were assigned numeric values 0 through 4,
respectively.
INVESTIGATOR GLOBAL ASSESSMENT OF DISEASE STATUS
VAS
“Make a global assessment of the patient’s disease
status by marking an (X) on the line below.” 100 mm VAS
scale—Left hand marker “Very well”, right hand marker
“Very poor.”
Likert
“Make a global assessment of the patient’s disease
status by marking an (X) in one box below.” Very well, Well,
Fair, Poor, Very poor. For analysis, the responses were
assigned numeric values 0 through 4, respectively.
WOMAC VA 3.0 OA INDEX QUESTIONNAIRE WITH A 0–100 MM VAS
RESPONSE SET
The WOMAC Pain Subscale asks “How much pain do
you have?” for each of five situations; each was rated on a
0–100 mm VAS. The five situations are walking on a flat
surface, going up or down stairs, at night while in bed,
sitting or lying, and standing upright5. For purposes of this
exercise, the WOMAC Pain Subscale (average of five pain
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questions) was also compared to the Likert scale Pain
response because it is widely used and was the primary
endpoint in the study which generated the data for this
analysis.
In order to increase patients’ understanding of VAS use,
a standardized training video was shown to each patient
prior to study start. This was not done with the Likert scale
because it was felt that the Likert response set was
self-explanatory. Thus, the comparisons in this article are
between an enhanced VAS approach vs an unenhanced
Likert approach to measuring OA efficacy.
STATISTICAL ANALYSES
The distribution (plots and summary statistics) of VAS
scores at each timepoint was summarized within each
baseline Likert scale category to examine the numeric
relationship of Likert score to VAS score by time. Cumu-
lative distribution plots were provided to display the percent
of patients with values exceeding every observed VAS
value; mean and median were computed to describe the
location of the “center” of the distribution; and standard
deviation (SD) and inter-quartile range (the difference be-
tween the 75th and 25th percentiles) were computed to
quantify the spread of the data. These summaries were
made for each Likert/VAS pair.
Change from baseline (at all on-treatment timepoints:
Weeks 1, 2, 4, 6 and discontinuation) in each of the Likert
scale variables mentioned in the Objectives was cate-
gorized (e.g., 4→4, 4→3, 4→2, 4→1, 4→0, 3→4, 3→3,
etc., where 4, 3, 2, 1, and 0, represent the descriptors
(“very well”, “well”, etc.) detailed in the previous section).
The distribution of the associated VAS changes within each
of these Likert change categories was summarized via
box-plots, cumulative distribution plots, and summary
statistics for each Likert/VAS pair of endpoints. The location
and dispersion of the data were summarized by mean and
SD, respectively. Although the cumulative distribution plots
revealed the typical s-shaped curve approximating a
normal distribution curve, median and inter-quartile range
were also calculated to corroborate the relationships
revealed by the means and SD’s.
Pearson correlation coefficients between VAS and Likert
endpoints for change from baseline and at baseline were
computed to assess the strength of a linear relationship
between the two scales. Coefficients from 0 to 0.2 indicate
none or nearly no linear relationship, 0.2 to 0.4 indi-
cate weak linear relationship, 0.4 to 0.6 indicate a moderate
degree of linear relationship, 0.6 to 0.8 indicate strong
linear relationship, and values from 0.8 to 1.0 indicate very
strong linear relationship.
In order to assess whether the data from the pairs of
Likert and VAS questions could be combined across end-
points to increase precision of the estimates of the relation-
ship (i.e., the calibration of the VAS in terms of category of
Likert scale response), analysis of variance (ANOVA) was
performed to assess the dependent variable “VAS change
from baseline” as a function of independent variables for
endpoint, timepoint, and their interaction.
Percent change, and natural log of the on-treatment (A)
vs baseline (B) ratio (ln(A/B)) was investigated to determine
if more consistent relationships between VAS and Likert
responses could be revealed in comparison to actual
change from baseline. This was addressed by assessing
random errors (i.e., residuals) from the above ANOVA for
normality and variance homogeneity using the Shapiro–
Wilk and Hartley’s maximum variance ratio statistics,
respectively.
During the assembly of the results, it was hypothesized
that patients may become accustomed, or learn how to
answer the VAS. To examine this, the variability of VAS
scores was assessed in the small subset of patients whose
category of Likert scale response did not change at the
screening, and Week 1, 2, 4, and 6 visits. If the variability of
VAS responses remained stable among these visits, then
there would be no learning effect. However, if the variability
would get smaller over time, then this could be a signal of
some learning effect of the VAS. (Note that patients were
not permitted to see their previous VAS responses.)
Results
DISTRIBUTION OF VAS SCORES BY LIKERT CATEGORY OF
RESPONSE
Examination of the distributions of VAS scores for each
Likert category of response at all the visits revealed gener-
ally s-shaped cumulative distributions indicating that they
could be approximated by a normal distribution. Examples
of these curves are shown for baseline Likert score of 3 in
Fig. 1a through d. Hence, mean and SD were used to
estimate location and variability (dispersion) parametrically.
Median and inter-quartile range showed similar results as
mean and SD, respectively.
At each individual timepoint, increments in VAS score
between adjacent categories of Likert response ranged
from 10 to 25 mm (Table I). In every case, mean VAS
scores increased with increasing Likert score. Mean VAS
values were generally similar in magnitude within each
Likert value across baseline and weeks 1 to 6 with two
exceptions. The first exception was larger mean VAS
values at baseline within Likert values 1 and 2 only. For
example, for Likert category 1, overall pain mean VAS
score was 51 at baseline, and ranged from 20 to 26 across
Weeks 1 to 6; for Likert category 2, mean at baseline was
63, and ranged from 53 to 58 at Weeks 1 to 6. The second
exception was that screening mean VAS values were
generally smaller than those at Weeks 1 to 6 within each
Likert category 3 and 4; however, they were similar in
categories 1 and 2, and larger in category 0, although the
numbers of patients contributing are small at the extreme
Likert categories 0 and 4. Summary statistics at both ends
of the Likert scale are based on small sample sizes, and,
therefore, may be unreliable. Refer to Table I for more
detail.
SD’s were generally similar across all timepoints within
VAS categories, and generally smaller at the ends of the
Likert scale within all timepoints. Similar relationships were
seen for medians as were seen for means, and similar
relationships were seen for inter-quartile ranges as were
seen for SD’s (data not shown).
DISTRIBUTION OF VAS SCORE CHANGES FROM BASELINE FOR
EACH CATEGORY OF LIKERT SCALE CHANGE FROM BASELINE
Figure 2a through d show box-plots of the distribution of
VAS changes for each category of Likert pre/post combina-
tion. The relationship between the VAS and Likert changes
are summarized by median and inter-quartile range as
shown in box-plots, and by mean and SD as listed in Table
II. With regard to location, as shown in Fig. 2a through d
and Table II, in every case, the magnitude of change
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from baseline in VAS increased with increasing change
from baseline for each category of Likert score change
from baseline. With regard to spread in the data, middle
categories of Likert scale change from baseline tended to
spread more than those at the extremes. For example, the
SD of VAS change from baseline was 10 for category of
Likert change from 3 at baseline to 0 on treatment and to 4
on treatment in comparison to SD’s of 14, 13, and 12 for
category of Likert change from 3 at baseline to 1, 2, and 3
on treatment, respectively. Similar patterns were seen for
other endpoints and other categories of Likert changes.
However, in nearly all cases, there was a wide range of
Fig. 1. Cumulative distributions of VAS changes from baseline for on-treatment Likert scale responses of 0, 1, 2, 3, and 4 from baseline Likert
scale response 3 (Panel A, Overall Pain; Panel B, WOMAC Pain Subscale; Panel C, Patient Global Assessment of Disease Status; Panel
D, Investigator Global Assessment of Disease Status).
Table I
Mean±SD (N) of VAS values (mm) by likert value at each visit
Likert value Week −1 Week 0 Week 1 Week 2 Week 4 Week 6
Investigator Global Assessment of Disease Status
0 8±4 (11) n/a 10±6 (19) 8±4 (33) 9±5 (42) 8±5 (48)
1 24±11 (73) 40±14 (8) 25±11 (69) 24±11 (82) 23±10 (69) 24±11 (70)
2 47±12 (105) 58±11 (48) 49±12 (72) 45±11 (53) 50±14 (53) 49±11 (42)
3 66±11 (15) 73±8 (137) 73±9 (37) 75±10 (32) 75±9 (34) 74±9 (38)
4 64± (1) 84±7 (16) 91±7 (6) 90±10 (9) 92±6 (11) 92±6 (11)
Overall pain question
0 34±32 (2) n/a 4±2 (8) 7±9 (12) 7±7 (12) 5±4 (27)
1 27±15 (75) 51±6 (6) 26±18 (70) 21±15 (77) 20±16 (84) 21±14(68)
2 48±15 (103) 63±14 (66) 56±17 (81) 57±16 (85) 58±16 (67) 53±18 (75)
3 62±12 (23) 80±11 (120) 79±10 (35) 81±9 (27) 76±14 (36) 79±12 (30)
4 59±16 (2) 92±5 (18) 90±10 (9) 90±10 (8) 91±9 (10) 91±9 (9)
Patient Global Assessment of Disease Status
0 11±12 (7) n/a 8±13 (14) 9±15 (19) 5±5 (22) 5±5 (32)
1 27±16 (57) 41±16 (15) 28±16 (68) 26±15(75) 21±14 (73) 23±14 (73)
2 48±13(116) 58±15 (73) 52±15 (73) 50±16 (76) 54±15 (73) 51±16 (63)
3 63±14 (19) 73±12 (98) 73±12 (40) 73±17 (29) 78±12 (30) 77±14 (30)
4 77±15 (4) 89±6 (21) 94±4 (6) 95±2 (7) 95±2 (8) 91±11 (8)
WOMAC Pain Subscale
0 15±8 (2) n/a 4±2 (8) 7±6 (12) 6±4 (12) 7±6 (27)
1 27±13 (74) 17±7 (6) 24±15 (70) 20±13 (77) 19±14 (84) 20±13 (68)
2 46±16 (102) 51±18 (66) 48±16 (80) 48±16 (84) 50±16 (66) 46±18 (74)
3 57±17 (23) 67±16 (119) 71±12 (36) 67±17 (27) 67±18 (36) 71±16 (30)
4 67± 6 (2) 75±15 (18) 81±12 (8) 82±13 (7) 82±11 (9) 83±12 (8)
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VAS changes associated with each level of Likert change
for each Likert baseline value.
ANALYSIS AIMED AT COMBINING CATEGORIES OF LIKERT SCALE
CHANGE FROM BASELINE
Table II shows the mean VAS changes from baseline for
each Likert category of change from baseline for each
endpoint. For each category of Likert change from base-
line, ANOVA results indicated significant differences for
mean VAS changes depending on baseline Likert score;
hence, VAS changes cannot be combined across Likert
baseline categories to assess relationship to corresponding
Likert changes. For example, for Investigator Assessment
of Disease Status, mean VAS changes for a Likert change
of zero increased with increasing baseline Likert scores
(means −18, −11, 0, and +9 for baseline Likert scores 1, 2,
3, and 4, respectively). A similar but less pronounced
relationship was seen for Patient Assessment of Disease
Status, WOMAC Pain Subscale, and Overall Pain Assess-
ment. Thus, for the less severe baseline Likert categories
(1 and 2), no change in Likert response was, on average,
associated with some level of improvement detected by
VAS.
For all four endpoints, mean VAS changes for a Likert
improvement of −1 decreased (in absolute value, i.e.,
showed less improvement) with increasing baseline Likert
categories. For example, mean changes in Overall Pain
were −51, −40, −25, and −7 for baseline Likert scores 1, 2,
3, and 4, respectively. The same general relationship was
seen for Likert improvements of 2 units (i.e., a change of
−2). This probably reflects more noticeable improvements
when Likert scores change 1 or 2 units from lower base-
lines. Mean improvements of 3 Likert units are only possi-
ble for baseline Likert scores of 3 or 4; for these categories
of Likert change, mean VAS changes were largest (see
Table II). Generally similar relationships were seen in
similar examinations of changes from screening to baseline
values. This is further evidence for not being able to
combine categories of Likert changes across Likert base-
lines.
CORRELATIONS BETWEEN VAS AND LIKERT SCORES
Pearson correlation coefficients for each endpoint were
measured for change from baseline, at baseline, and at
screening. To assess correlations for change from base-
line, the data were averaged within each patient across
the 6 week treatment period (the primary endpoint of the
study), and also assessed for change from baseline to the
last observed timepoint.
Correlation coefficients for average change from base-
line across the 6-week treatment period between VAS and
Likert scales were 0.84, 0.76, and 0.73 for Investigator
Global, Patient Global, and Overall Pain, respectively; the
correlation between WOMAC Pain Subscale on the VAS
and Overall Pain on the Likert Scale was 0.68. For change
from screening to baseline, these values were smaller,
0.68, 0.46, 0.37, and 0.13, respectively. For change from
baseline to last observed on-treatment value up to Week 6,
these values were 0.85, 0.76, 0.74, and 0.71, respectively.
Correlation coefficients at baseline were 0.72, 0.68, 0.66,
and 0.38, respectively. Thus, except for the change from
screening to baseline visit, there were strong correlations
Fig. 2. Box-plots of distributions of VAS changes from baseline for all combinations of Likert scale baseline and on-treatment responses
(Panel A, Overall Pain; Panel B, WOMAC Pain Subscale; Panel C, Patient Global Assessment of Disease Status; Panel D, Investigator
Global Assessment of Disease Status). [Definitions of the Box-plots: the ends of the boxes represent the 25th and 75th percentiles; the
horizontal line inside the box represents the median (50th percentile); the vertical lines ending at ‘T’ represent distance from the median of
1.5 times the difference between the 25th and 75th percentiles; all data except outliers should fall within the ‘T’s’; outliers would have been
shown as ‘*’ lying beyond the ‘T’s’.]
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Table II
Summary statistics of change in VAS (mm) for categories of change in Likert scale response
Likert values Mean±SD (N) Mean difference
from treatment
Likert value 0
Median [iqr] Median difference
from treatment
Likert value 0Baseline Treatment Change
Overall pain question
1 0 −1 −51±11 (2) n/a −51[15] n/a
1 0 −40±7 (19) 11 −39[9] 12
2 +1 3±23 (2) 42 3[33] 42
3 +2 7± (1) 5 7[0] 5
4 +3
2 0 −2 −56±15 (34) n/a −59[23] n/a
1 −1 −40±17 (125) 17 −40[25] 19
2 0 −10±21 (87) 29 −10[30] 30
3 +1 −1±16 (14) 9 5[15] 15
4 +2 18±0 (3) 19 18[0] 13
3 0 −3 −69±10 (20) n/a −70[8] n/a
1 −2 −53±18 (144) 16 −55[25] 15
2 −1 −25±17 (191) 28 −26[25] 29
3 0 −3±11 (88) 21 −3[16] 24
4 +1 9±15 (29) 13 11[20] 14
4 0 −4 −87±5 (3) n/a −84[8] n/a
1 −3 −73±18 (11) 13 −73[32] 11
2 −2 −37±15 (28) 36 −39[25] 34
3 −1 −7±11 (25) 30 −5[7] 34
4 0 2±0 (4) 9 2[0] 7
WOMAC Pain Subscale
1 0 −1 −10±8 (2) n/a −10[11] n/a
1 0 −9±7 (19) 0 −11[12] -1
2 +1 15±13 (2) 24 15[19] 26
3 +2 45± (1) 30 45[0] 30
4 +3 (0)
2 0 −2 −39±20 (34) n/a −37[34] n/a
1 −1 −28±17 (125) 12 −29[27] 8
2 0 −6±13 (87) 22 −4[18] 25
3 +1 1±14 (14) 6 0[11] 4
4 +2 19±0 (3) 19 19[0] 19
3 0 −3 −55±15 (20) n/a −60[25] n/a
1 −2 −42±19 (144) 13 −42[25] 17
2 −1 −19±16 (187) 23 −18[19] 24
3 0 1±12 (89) 20 3[12] 21
4 +1 27±20 (25) 26 27[37] 24
4 0 −4 −75±5 (3) n/a −77[8] n/a
1 −3 −68±10 (11) 7 −70[20] 7
2 −2 −36±17 (28) 32 −36[15] 34
3 −1 4±25 (25) 40 −5[20] 31
4 0 8±0 (4) 4 8[0] 13
Patient Global Assessment of Disease Status
1 0 −1 −30±18 (14) n/a −22[33] n/a
1 0 −7±19 (35) 22 −8[27] 14
2 +1 −2±20 (11) 5 0[37] 8
3 +2 (0)
4 +3 (0)
2 0 −2 −52±13 (38) n/a −50[12] n/a
1 −1 −30±18 (123) 21 −27[26] 23
2 0 −9±20 (104) 21 −8[24] 19
3 +1 6±21 (23) 15 0[36] 8
4 +2 37±0 (3) 31 37[0] 37
3 0 −3 −66±13 (30) n/a −66[16] n/a
1 −2 −47±19 (110) 19 −50[23] 17
2 −1 −21±16 (144) 26 −22[25] 28
3 0 −3±11 (84) 18 −3[15] 19
4 +1 13±8 (17) 17 14[14] 17
4 0 −4 −76±21 (5) n/a −85[25] n/a
1 −3 −57±19 (21) 19 −59[27] 26
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between VAS and Likert scale responses in measuring the
three endpoints and between the WOMAC Pain Subscale
(VAS) and Overall Pain (Likert). Correlations for change
from screening to baseline were modest to strong, except
for the WOMAC and Overall Pain variables. These excep-
tions could be due to the homogeneity of patient response
to withdrawal of NSAID; i.e., since patients were all
worsening similarly, it was more difficult to demonstrate
high correlation in such a narrow range of response. That
is, a small variation occurring in a narrow range would
appear as a small correlation.
ANALYSIS AIMED AT COMBINING ENDPOINTS (TO ASSESS
VAS/LIKERT RELATIONSHIP WITH MORE PRECISION)
For each of the Likert and VAS response scales, the
change from baseline data at Weeks −1 (Screening), 1, 2,
4, and 6 for the Overall Pain, Patient Global, and Investi-
gator Global variables were combined for analysis to
assess whether similar changes were observed across the
various timepoints and across the variables. If they would
be found similar, then the endpoints could be combined for
more precise estimation of the statistics summarizing the
VAS relationship to Likert. The mean changes from base-
line were assessed via ANOVA with independent variables
endpoint and Week.
The interaction between endpoint and Week was tested
and did not approach significance (p>0.5), so differences
among endpoints were consistent across Weeks, and vice
versa. This justifies the combination of the data across
study weeks to generate the data summaries presented
thus far. Mean change from baseline differed significantly
across endpoints. Hence, combining the endpoint distri-
butions to assess the VAS/Likert relationship is not clearly
straightforward since their distributions were shifted and
since these shifts among endpoints were different on the
Likert and visual analog scales.
ASSESSMENT OF PERCENT CHANGE AND NATURAL LOG OF
ON-TREATMENT TO BASELINE RATIO FOR DESCRIBING THE
VAS/LIKERT RELATIONSHIP
The magnitudes of percent changes in VAS from base-
line to Study Weeks 1, 2, 4, and 6 were compared with
corresponding discrete Likert scale changes. (Note that it
does not seem to make good sense to assess Likert Scale
percent changes because of their discrete nature.)
The distributions of the actual VAS changes were closer
to normality than those of percent change and of natural
log (of on-treatment/baseline ratio) for each endpoint. Also,
the variances of the actual VAS changes were more
homogeneous than those of percent change and of natural
log (of on-treatment/baseline ratio) for each endpoint.
In general, where there was sufficient sample size to
yield reliable estimates, the differences between mean
percent changes in VAS response for adjacent Likert scale
categories were mostly between 20 and 40 percentage
points (ranged from 12 to 70). Differences in median
percent change responses were generally similar. (Detailed
summary tables are not included to conserve space.)
Like the results for actual change from baseline, ANOVA
of VAS percent change as a function of baseline showed
significant differences among the baselines at most values
of Likert change for each endpoint. Thus, the mean VAS
percent change cannot be computed in a combined fashion
across baseline values for the same value of Likert change.
Table II
Continued
Likert values Mean±SD (N) Mean difference
from treatment
Likert value 0
Median [iqr] Median difference
from treatment
Likert value 0Baseline Treatment Change
2 −2 −33±16 (26) 24 −34[23] 25
3 −1 −10±13 (22) 23 −4[12] 30
4 0 −4±10 (9) 6 1[6] 5
Investigator Global Assessment of Disease Status
1 0 −1 −31±16 (17) n/a −34[30] n/a
1 0 −18±18 (13) 13 −15[38] 19
2 +1 −10± (1) 8 −10[0] 5
3 +2 3± (1) 13 3[0] 13
4 +3
2 0 −2 −48±14 (39) n/a −44[17] n/a
1 −1 −37±17 (77) 11 −36[23] 8
2 0 −11±14 (42) 26 −13[17] 24
3 +1 11±11 (30) 22 11[13] 24
4 +2 14±0(3) 3 14[0] 3
3 0 −3 −63±10 (80) n/a −62[13] n/a
1 −2 −47±14 (188) 16 −49[17] 14
2 −1 −25±13 (158) 22 −25[17] 24
3 0 −0±12 (88) 24 −1[17] 25
4 +1 18±10 (29) 18 20[19] 21
4 0 −4 −72±6 (6) n/a −73[11] n/a
1 −3 −59±9 (12) 14 −56[15] 17
2 −2 −33±13 (19) 26 −34[21] 22
3 −1 −12±6 (22) 21 −12[3] 22
4 0 9±5 (5) 22 13[9] 25
iqr, inter-quartile range; i.e., 75th percentile minus 25th percentile.
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EFFECT SIZES OF VAS AND LIKERT RESPONSE SCALES
The relative utility of the VAS and Likert response scales
in clinical trials was assessed by their effect sizes (the
magnitude of difference between active treatment and
placebo divided by the pooled SD; this expresses the
magnitude of difference in units of SD). Table III shows
the effect sizes for the difference between the combined
rofecoxib doses (because they demonstrated similar levels
of efficacy1) vs placebo in the trial. The effect sizes were
generally similar in magnitude for the VAS and Likert scale,
but only slightly larger for VAS. Effect sizes within each
variable were all larger for the overall average (across the
6-week treatment period) change from baseline in compari-
son to change from baseline to the last observed value.
POTENTIAL FOR LEARNING EFFECTS ON THE VAS
The average and median SD’s of the last 3 and last 2
VAS observations were smaller than those of all obser-
vations for all endpoints and every category of Likert scale
response for which the sample size exceeded three
patients (Table IV), consistent with a learning effect for VAS
responses over time.
Discussion
In this OA study, Likert scale responses are highly
correlated with VAS responses, and both generate similar
precision when comparing active treatment to placebo. In
addition, the results suggest that when analyzing clinical
trial data for treatment effects in OA, VAS response can be
measured using simple difference from baseline. There
was no gain in precision, in closeness to normality, or in
closeness to homogeneity of variance if percent change or
log of on-treatment to baseline ratio were used instead of
difference from baseline. Finally, the results suggest ad-
ditional ways in which efficacy data from OA trials can be
assessed to compare the relative efficacy across treat-
ments and the relative quality of the efficacy information
across trials.
A change between adjacent categories of Likert scale
response (i.e., of 1 unit) yields different VAS mean changes
depending on the category of Likert baseline score—
decreasing VAS improvements for increased severity of
Likert baseline category. So it’s uncertain what a specific
change in VAS means for an individual patient. The closer
to the middle of the scale, the more stable the relationship.
Since the Likert response categories are labeled with
words, they have face validity and the changes are well
defined. The question of whether a one point Likert change
from different baselines demonstrates the same magnitude
of improvement is unknown; but this pitfall of the Likert
scale exists for the VAS, as well.
For some Likert scores and some changes in Likert
scores, the associated VAS values can vary across a very
wide range, indicating large variability between patients’
VAS responses for individual discrete Likert scale re-
sponses. Since the Likert scale responses are anchored by
words, this variability may be detrimental to the precision of
the VAS to discriminate between treatments. The potential
gain in precision due to continuous measurement may be
offset by this variability since effect sizes are generally
similar between VAS and Likert scale endpoints. The VAS
variability does decrease at the extremes of the Likert
response scale, as is expected due to ceiling/floor effects.
Distributions of actual VAS values were closer to normal-
ity and homogeneity of variance than percent change and
log-transformed VAS values. Hence there appeared to
be no advantage of using percent change or log transfor-
mation over the actual change in VAS.
The Likert scale is easier to use than the VAS for two
major reasons. First, it is easier for a patient to understand
the check-boxes each associated with a word or phrase
Table IV
Average and median SD’s of all, last 3, and last 2 VAS observations for those patients with all Likert responses the same at all visits except
baseline (Weeks −1, 1, 2, 4, 6)
Endpoint Likert category Number of
patients†
Average SD across
timepoints
Median SD across
timepoints
All Last3 Last2 All Last3 Last2
Investigator Global Assessment of Disease Sta-
tus
1 4 4.9 3.7 2.7 4.4 3.4 1.8
2 7 8.9 7.2 6.6 11.2 5.5 4.9
Overall pain question 1 11 11.3 9.6 8.9 8.5 7.1 7.1
2 11 12.7 10.3 9.4 11.4 8.7 4.9
Patient Global Assessment of Disease Status 1 9 8.2 7.2 6.8 7.2 6.0 5.7
2 9 10.6 9.0 8.2 10.8 8.1 8.5
Womac Pain Subscale 1 11 7.8 4.7 3.6 6.3 3.5 1.8
2 11 11.5 7.4 4.4 11.4 6.5 4.2
†Number of patients with the same category of Likert scale response at all visits except the baseline (Weeks −1, 1, 2, 4, and 6).
Table III
Effect sizes† for VAS and Likert scale responses
Change from baseline Scales Overall pain Patient Global Inv. Global WOMAC Pain
Average across treatment period VAS 1.08 1.15 1.33 1.04Likert 1.05 1.10 1.28 Not measured
Last observed value over 6 weeks VAS 0.89 1.00 1.09 0.89Likert 0.86 0.88 1.04 Not measured
†Mean difference between combined rofecoxib groups vs placebo divided by the pooled SD.
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rather than marking an X on a continuous line anchored
with words only at both ends. Second, the Likert is easier to
score since each check-box results in a unique, easily read
response item in comparison to the measurement neces-
sary to use the VAS. This pitfall of the VAS can, however,
be overcome by using a 0–100 numeric rating scale; others
have shown the usefulness of such a numeric scale7.
Another down-side to the VAS is that photocopying VAS
response scales can change the length of the scale a few
millimeters. This can lead to increased variability depend-
ing on how many times the copies are copied to make the
blank case report forms. For these reasons, and since the
Likert scale responses correlate highly with, and have
similar precision as their corresponding VAS responses,
Likert scales may be more useful in clinical trials than
VAS’s. Several others have demonstrated similar effect
sizes for VAS and Likert scales5–10.
The percent of patients with large changes may be useful
in discriminating between active treatments because rela-
tionships between VAS and Likert scales are clearer (i.e.,
tighter). Changes between adjacent categories of Likert
scale response (1 unit) have large variability—changes of 2
units yield tighter variability. For example, from Table II, for
the overall pain question, the ratio of VAS SD to mean
change from baseline (inverse of within-treatment group
effect size) was 1.6, 0.41, 0.25, and 0.06 for categories of
Likert changes 4 to 3, 4 to 2, 4 to 1, and 4 to 0, respectively;
was 0.68, 0.34, and 0.14 for Likert changes 3 to 2, 3 to 1,
and 3 to 0, respectively; and was 0.43 and 0.27 for Likert
changes 2 to 1 and 2 to 0, respectively. Most of these
reductions were due to increases in mean VAS improve-
ment, but some of it was due to tighter variability (smaller
SD’s) for the larger improvements. Similar relationships
were seen for the other endpoints. However, the largest
percentage point differences between the active treatment
and placebo groups were produced by using moderately
large VAS cutoffs of improvement. Depending on the end-
point, cutoffs of 11–18 mm of VAS improvement led to the
largest percentage point differences between the active
and placebo treatments for most endpoints examined.
However, in some cases improvements as large as 40 mm
yielded maximum percentage point differences (data not
shown).
The effect sizes were generally similar in magnitude for
the VAS and Likert scale; thus each should provide similar
precision for assessing OA efficacy. Effect sizes within each
variable were all larger for the overall average (across
the 6-week treatment period) change from baseline in
comparison to change from baseline to the last observed
value. This is not surprising since use of the average tends
to decrease variability (because it incorporates information
from multiple assessments), and the level of treatment
response was generally similar across time1. Thus, the
average response tends to integrate the treatment differ-
ences observed at each week.
Smaller SD’s were seen at later time points than earlier
time points, consistent with some learning effect on VAS
scores. Further study is required to assess if this is a
detriment to using VAS scores.
Examination of the relationship between Likert and VAS
responses may be useful to assess the internal consistency
of efficacy results within a trial and to compare quality of
efficacy results across trials. Within a trial, the degree of
association between VAS and Likert responses could be
used as a measure of internal consistency of efficacy
results. Across Trials, Likert global response may be useful
as an anchor to measure goodness of trial based on the
degree of spread found in the VAS endpoints. That is, those
trials with VAS results which most closely “match” (more
consistent mean and less SD) the Likert global response
anchor may be the best trials. This is also a function of
inclusion/exclusion criteria which could produce a more or
less homogeneous group of patients studied.
In summary, VAS and Likert scale responses are highly
correlated and yield similar precision for discriminating
active from placebo treatment in OA patients. Since Likert
scale responses are easier to administer and interpret, it
may be preferable to use them to measure OA response.
Although not assessed in this study, a 0–10 point discrete
scale may be the most useful compromise, incorporating all
positive attributes of both the visual analogue and Likert
scale responses; however, this requires further study.
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